On Thursday, October 29th, Ryo Asahina, Senior BioEngineer at Chitose Laboratory Corp., will present a research poster at The 33rd ESGCT Annual Congress, organized by European Society of Gene & Cell Therapy.

The presentation, titled “Process development of a HAT cell–based rAAV manufacturing platform for enhanced genome packaging and scalable vector production,” will showcase our progress in recombinant adeno-associated virus (rAAV) vector production using HAT cells*, explaining how these efforts aim to increase full-capsid genome packaging rates, optimize production efficiency, and pave the way for future large-scale manufacturing.

*HAT cells resulted from research supported by AMED under Grant Number JP18ae0201001 and JP24se0123004.

Event Overview
Event Name: The 33rd ESGCT Annual Congress
Date and Time: Tuesday, October 27 – Friday, October 30, 2026 (Local Time)
*CHITOSE poster presentation will take place on Thursday, October 29, 14:00–16:00 (Local Time).
Venue: CCH – Congress Center Hamburg, Germany
Organizer: The European Society of Gene and Cell Therapy (ESGCT)
Poster Title: Process development of a HAT cell–based rAAV manufacturing platform for enhanced genome packaging and scalable vector production
Poster Number: P0772
Registration: Please refer to the official website for details.

Related Information
[External] The 33rd ESGCT Annual Congress
[Press Release] High-Performance Novel HAT Cell Line for Gene Therapy, Published in Molecular Therapy Methods & Clinical Development, and Ready for Commercial Use
[Press Release] Establishing an AAV Manufacturing Platform Using Domestic HAT Cells: A New Step Toward Practical Application and Expansion of Gene Therapy (Japanese)